XOMA Royalty (XOMA) Other Non-Current Liabilities (2010 - 2026)
XOMA Royalty (XOMA) reported Other Non-Current Liabilities of $3.7 million for Q1 2026, up 12.0% on a YoY basis from $3.3 million in Q1 2025, and up 2.89% sequentially from $3.6 million in Q4 2025.
XOMA Royalty (XOMA) Other Non-Current Liabilities (2010 - 2026) Analysis & Trends
XOMA Royalty (XOMA) has 15 years of Other Non-Current Liabilities data on file, last reported at $3.7 million in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Liabilities rose 12.0% year-over-year to $3.7 million; the trailing twelve-month figure through Mar 2026 stood at $3.7 million (up 12.0% YoY), and the FY2025 full-year result was $3.6 million, up 12.01% from the prior year.
- Other Non-Current Liabilities rose to $3.7 million in Q1 2026, from $3.6 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $3.7 million in Q1 2026 to a low of $2.9 million in Q2 2024.
- A 3-year average of $3.3 million and a median of $3.3 million in 2025 frame the typical range for Other Non-Current Liabilities.
- Across the five-year window, Other Non-Current Liabilities increased 16.43% in 2025 and climbed 12.0% in 2026, its largest moves.
- Tracing XOMA's Other Non-Current Liabilities over 3 years: stood at $3.2 million in 2024, then gained by 12.01% to $3.6 million in 2025, then increased by 2.89% to $3.7 million in 2026.
- Business Quant data shows XOMA's Other Non-Current Liabilities at $3.7 million in Q1 2026, $3.6 million in Q4 2025, and $3.4 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | XOMA Royalty | 478.42 Mn | 412.34 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.70 Mn |
| Dec 31, 2025 | 3.60 Mn |
| Jun 30, 2025 | 3.40 Mn |
| Mar 31, 2025 | 3.31 Mn |
| Dec 31, 2024 | 3.21 Mn |
| Sep 30, 2024 | 3.13 Mn |
| Jun 30, 2024 | 2.92 Mn |
| Sep 30, 2021 | 20,000.00 |
| Jun 30, 2021 | 20,000.00 |
| Mar 31, 2021 | 102,000.00 |
| Dec 31, 2020 | 50,000.00 |
| Sep 30, 2020 | 134,000.00 |
| Jun 30, 2020 | 35,000.00 |
| Mar 31, 2020 | 200,000.00 |
| Dec 31, 2019 | 43,000.00 |
| Sep 30, 2019 | 457,000.00 |
| Jun 30, 2019 | 294,000.00 |
| Mar 31, 2019 | 100,000.00 |
| Dec 31, 2018 | 590,000.00 |
| Sep 30, 2018 | 834,000.00 |